Nasdaq exas.

The average one-year price target for EXAS / Exact Sciences Corp. is $112.948. The forecasts range from a low of $85.85 to a high of $136.5. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to ...Exact Sciences Corporation EXAS recently presented modeling data that shows Cologuard (mt-sDNA) as the most cost-effective colorectal cancer (CRC) detection and screening option at the 2021 ...Investing in Exact Sciences (NASDAQ:EXAS) a year ago would have delivered you a 59% gain. Exact Sciences Corporation ( NASDAQ:EXAS ) shareholders might be concerned after seeing the share price ...Sep 9, 2023 · Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ... More from Nasdaq ; WesBanco, Inc. [WSBC] Rings the Nasdaq Opening Bell. 1 day ago · 623 views ; This #GivingTuesday, we're reimagining a world built on s · 1 day ...

Board. Exact Sciences to participate in November investor conferences. November 01 2023 - 06:00AM. PR Newswire (US) MADISON, Wis., Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ...In the past 30 days, the Zacks Consensus Estimate for Exact Sciences’ loss for 2023 has remained constant at $1.90 per share. The Zacks Consensus Estimate for 2023 revenues is pegged at $2.46 ...

EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission. Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com. Published. May 23, 2022 11:22AM EDT. Exact Sciences Corporation EXAS is well-poised for growth, backed by impressive first-quarter 2022 results. Further, the company’s legacy Screening business ...

Exact Sciences (NASDAQ:EXAS) produces and sells diagnostic and cancer screening tests. The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ...Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt Oct 04. Price target increased by 7.0% to US$109 Sep 19. Exact Sciences Corporation (NasdaqCM:EXAS) agreed to acquire Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A). Sep 13. Executive VP & CFO notifies of intention to sell stockExact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewha... Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last qu...According to the issued ratings of 16 analysts in the last year, the consensus rating for Exact Sciences stock is Moderate Buy based on the current 4 hold ratings and 12 buy ratings for EXAS. The average twelve-month price prediction for Exact Sciences is $96.56 with a high price target of $130.00 and a low price target of $73.00.

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) saw a large growth in short interest during the month of October.As of October 15th, there was short interest totalling 8,170,000 shares, a ...

EXAS earnings call for the period ending March 31, 2023. Image source: The Motley Fool. Exact Sciences ( EXAS 0.14% ) Q1 2023 Earnings Call May 09, 2023 , 5:00 p.m. ET

Find the latest Institutional Holdings data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.EXACT SCIENCES CORP ( EXAS) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...01 Nov, 2023, 06:00 ET. MADISON, Wis., Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ), a leading provider of cancer screening and diagnostic tests, today announced that company ...Get the latest Exscientia PLC (EXAI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.In trading on Friday, shares of EXACT Sciences Corp. (Symbol: EXAS) crossed below their 200 day moving average of $85.90, changing hands as low as $85.71 per share. EXACT Sciences Corp. shares are ...

MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23 ...Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 67.03 +3.03 (+4.73%) At close: 04:00PM ESTWebThe latest price target for . Exact Sciences (NASDAQ: EXAS) was reported by Goldman Sachs on November 3, 2023.The analyst firm set a price target for $90.00 expecting EXAS to rise to within 12 ...Direct. 3,000. $16.52. 42,830. Back to EXAS Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC ...Exact Sciences Corporation (NASDAQ:EXAS) is a Wisconsin-based molecular genetics company that is working on technologies related to early detection of cancers. Cathie Wood bought a stake in the ...Exact Sciences' sales will top $2 billion this year as the business continues to achieve impressive growth. ... NASDAQ: EXAS Exact Sciences. Market Cap. $12B. Today's Change (4.73%) $3.03.

17 Nov 2023 ... PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has ...

The last time Exact Sciences (NASDAQ: EXAS) announced its quarterly results, revenue increased 64% compared with the prior-year period. It was a different story on the company's bottom line ...Feb 16, 2021 · MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into an agreement to acquire Ashion Analytics, LLC (Ashion) from The ... Exact Sciences Corp (EXAS) latest news, insider trading and hedge fund ownership data provided by Insider Monkey. ... Exact Sciences Corporation (NASDAQ:EXAS) Q3 2023 Earnings Call Transcript.Nov 23, 2023 · EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ... Turning to the calls side of the option chain, the call contract at the $60.00 strike price has a current bid of $4.20. If an investor was to purchase shares of EXAS stock at the current price ...As of February 10, 2023, the average one-year price target for EXACT Sciences is $66.64. The forecasts range from a low of $35.35 to a high of $99.75. The average price target represents an ...Exact Sciences (NASDAQ: EXAS) and Guardant Health make diagnostic tests to help screen for cancer. The two healthcare stocks have similar price-to-sales (P/S) ratios, and over the past five years ...Exact Sciences' stock was down by 11.2% on sky-high volume as of 3:30 p.m. ET Wednesday afternoon. Although 2023 Q2 revenue jumped 19% year over year to $622 million, Wall Street apparently wanted ...

Exact Sciences Corp (EXAS) latest news, insider trading and hedge fund ownership data provided by Insider Monkey. ... Exact Sciences Corporation (NASDAQ:EXAS) Q3 2023 Earnings Call Transcript.

Exact Sciences Corporation EXAS continues to make significant progress with its Cologuard test. However, the pandemic-led continued business disruption is a concern. Exact Sciences currently ...

Exact Sciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 20th, 2024 based off last year's report dates. Learn more on EXAS's earnings history.NASDAQ: EXACT Sciences Corporation (EXAS) = 65.06 USD. Provided by Alpha Vantage. EXACT Sciences Corporation stock (EXAS) in USD. 1 EXAS = 65.06 USD. 1 month. 6 months. 1 year. 5 years. Hold over 40 currencies to convert and send money at any time. Open an account.Exact Sciences Company Info. EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non ...Exact Sciences's earnings have been declining at an average annual rate of -21.7%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 28.7% per year. This section of the company report contains some beta features. How Exact Sciences makes and spends money.Dec 1, 2023 · Exact Sciences Co. (NASDAQ:EXAS) announced its quarterly earnings results on Tuesday, August, 1st. The medical research company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.50) by $0.05. The medical research company earned $622.10 million during the quarter, compared to the consensus estimate of $601.14 ... 35,260.96. +172.67. 【日本経済新聞】エグザクト・サイエンシズ/EXACT Sciences [EXAS] の株価、チャート、業績推移、会社概要、ニュースなど米国株投資や ...Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after ...In trading on Friday, shares of EXACT Sciences Corp. (Symbol: EXAS) crossed below their 200 day moving average of $85.90, changing hands as low as $85.71 per share. EXACT Sciences Corp. shares are ...Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after ...Nov 23, 2023 · EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ...

The public float for EXAS is 179.16M, and currently, short sellers hold a 4.07% ratio of that floaft. The average trading volume of EXAS on November 30, 2023 was 1.42M shares. EXAS) stock’s latest price update. Exact Sciences Corp. (NASDAQ: EXAS)’s stock price has increased by 0.14 compared to its previous closing price of 64.97.Nasdaq | EXAS U.S.: Nasdaq Exact Sciences Corp. Watch NEW Set a price target alert Premarket Last Updated: Nov 30, 2023 7:29 a.m. EST Delayed quote $ 65.00 -0.06 -0.09% Before Hours Volume:...Exact Sciences Corporation Common Stock (EXAS) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.MADISON, Wis., Feb. 22, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $473 .8 million ...Instagram:https://instagram. rare u.s. quartersbest reit investmentsceo of exxonmobilnysearca vbr Exact Sciences was founded in 1995 in Marlborough, Massachusetts, by Stanley Lapidus and Anthony Shuber as a company focused on the development of a non-invasive test for colorectal cancer. The company eventually went public with an initial offering on the NASDAQ in 2001. what is q.ai6 month bond rate Exact Sciences EXAS Operating Losses;.Another 70% to Fall!! The EXAC chart has been a downtrend from $130 to $40 with a High VOLUME. The stock is making new bottoms while insiders and the executive team have constantly been selling at any price! The stock is down 70% from its high of $137! Get the latest Exscientia PLC (EXAI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. tractor supply power tools May 18, 2023 · On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ... Exact Sciences (EXAS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures ...In the quarter under review, Exact Sciences’ gross profit (excluding the amortization of acquired intangibles) rose 68% to $320.9 million. Gross margin expanded 276 basis points (bps) to 73.8% ...